Provided is a pharmaceutical composition containing a stable anti-human TSLP receptor antibody, which is obtained by controlling the production of chemically modified forms such as deamidated forms and oxidized forms, or decomposition products or polymers. The pharmaceutical composition contains anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
